Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine versus hydroxychloroquine + azithromycin in ICU patients with COVID-19
IRCT20200428047228N2Phase 3Completed
- Sponsor
- Quality Improvement of Intensive Care Research Center
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of hydroxychloroquine and azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Quality Improvement of Intensive Care Research Center. Primary endpoints: Duration of ICU stay, In-hospital death and 5 more. Started May 2020; status: completed.
02
Drugs
hydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200428047228N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200428047228N2.